Piroxicam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Piroxicam
- Piroxicam: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Piroxicam: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID), originally used for rheumatoid arthritis and osteoarthritis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare developmental disorder. Currently there are 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, osteoarthritis, arthropathy (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 99.996% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Piroxicam is a non-selective COX inhibitor, a class that reduces prostaglandin-mediated inflammation and pain. Its efficacy in rheumatoid arthritis and osteoarthritis is established.
The predicted disease is a rare developmental malformation syndrome affecting the eyes and skeleton. COX inhibition is not expected to act on the developmental pathways behind it. No plausible mechanistic link could be identified.
The very high score (99.996%) most likely reflects the structure of the knowledge graph, such as shared skeletal or musculoskeletal annotations, rather than real biology. Other top-ranked predictions show the same pattern: brachydactyly-syndactyly syndrome, Hunter-Thompson acromesomelic dysplasia, brachyolmia and similar conditions. None has any clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Seven valid single-ingredient licences are held, with no cancelled ones. Available forms are oral (tablet, capsule), injectable and topical (gel). The five main licences are listed below. The licence records contain no approved-indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN07791P | BREXIN TABLET 20 mg | Tablet | Chiesi Farmaceutici SpA |
| SIN06575P | ROSIDEN INJECTION 20 mg/ml | Injection | Shin Poong Pharmaceutical Co Ltd |
| SIN06131P | ROSIDEN CAPSULE 20 mg | Capsule | Shin Poong Pharmaceutical Co Ltd |
| SIN05491P | APO-PIROXICAM CAPSULE 10 mg | Capsule | Apotex Inc |
| SIN05893P | APO-PIROXICAM CAPSULE 20 mg | Capsule | Apotex Inc |
The remaining two licences are ROXIFEN GEL 500 mg/100 g (SIN10968P) and ROSIDEN GEL (SIN05100P).
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): The knowledge graph links piroxicam to the following conditions as contraindications or cautions:
- Cardiovascular: hypertension, congestive heart failure, myocardial infarction, coronary thrombosis, stroke and cerebrovascular disorders, cerebral infarction, and cardiovascular or heart disease in general.
- Renal and hepatic: kidney disease, liver disease, acute liver failure, hepatitis, drug-induced liver injury, gallbladder disease.
- Gastrointestinal: active peptic ulcer disease.
- Haematological: blood coagulation disease, thrombotic disease, anaemia, hemoglobinopathy.
- Other: vision disorder or blindness, substance abuse/dependence, pyoureter.
- Drug Interactions: The interaction check was completed and returned 100 records. The first 20 were available for review. Most were Moderate, and a few were Minor.
- Moderate: acetylsalicylic acid, corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), metformin, glimepiride, chlorpropamide, mesalazine, balsalazide, aprepitant, potassium citrate and potassium bicarbonate.
- Minor: famotidine, ranitidine, cimetidine and linaclotide.
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no trials, no literature and no plausible mechanism. It is most likely a knowledge-graph artefact. Piroxicam is well established and widely marketed in Singapore, but that does not support this new indication.
To proceed, the following is needed:
- Any supporting biological or clinical evidence linking COX inhibition to this syndrome; without it, further work is not justified.
- Detailed mechanism of action data and the full package insert warnings and contraindications.
- Further review of the rank 10 prediction, juvenile idiopathic arthritis, which has far better support (Evidence Level L3, score 99.93%). It rests on older piroxicam studies in children (a 1986 multicentre piroxicam vs naproxen study, a 1987 randomised comparison and a 1991 paediatric pharmacokinetic study) plus recent NSAID network meta-analyses. Study designs were not verified from full text, and no trials are registered. This indication is a more sensible research question than the top-ranked one.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.